Alice Goodman

Small renal masses identified in elderly patients can be safely managed by surveillance and maintain the same mortality risk as those who undergo surgery, suggesting that surgery could be avoided altogether in many patients.

Shortening the course of androgen blockade therapy from 36 months to 18 months when combined with radiation therapy does not appear to compromise outcomes in patients with high-risk prostate cancer

A large, retrospective study has found that high-risk prostate cancer that can only be detected through PSA testing is more likely to occur among men over the age of 75 and in African Americans.

A new paradigm that relies on identifying networks or clusters of single nucleotide polymorphisms can accurately predict which patients will develop treatment-related mucositis and other side effects.

Research is needed to justify the dollar savings achieved by a supportive care program, but it is not clear what should be measured and how studies should be designed to demonstrate this.

Nurse staffing varies from institution to institution, depending on many factors, both internal and external. To gain a better understanding of nurse staffing, ratios of nurses to patients, and productivity, a survey was sent to ONS members.

Although the role of adequate nutrition in cancer patients is gaining recognition as being important, the area is often neglected as a key component of nursing care.

Diagnostic tests are common across the spectrum of cancer care, but results may not always be easily interpreted or applied clinically.

Nurses involved in cancer care should be up to date on the growing number of applications for interventional radiology in oncology, since some centers may call upon them to work within the quickly developing area.

Recent evidence shows that some of the newer molecularly targeted therapies can cause diarrhea, which can lead to dose reductions and alterations.

Although molecularly targeted agents can cause cardiac damage, it appears to be reversible and related to cellular dysfunction, as distinct from agents such as anthracyclines that cause cellular death and irreversible cardiac dysfunction.

Adding brivanib alaninate to cetuximab had no survival advantage over cetuximab alone in patients with KRAS wild-type chemorefractory metastatic colorectal cancer.

New research on predictive and prognostic biomarkers for therapy targeting EGFR strongly suggests that panitumumab should be reserved for mCRC tumors with wild-type KRAS.

Optical biomarkers derived from nondysplastic metaplastic cells can detect the presence of high-grade dysplasia and adenocarcinoma from Barrett's esophagus.

Thanks to earlier detection and improved treatment, the population of cancer survivors has increased dramatically and will continue to increase as the baby boomers age.

Targeting the bone microenvironment appears to be a potential approach to treating prostate cancer.

The addition of everolimus to standard octreotide LAR achieved about a 5-month improvement in progression-free survival in patients with advanced neuroendocrine tumors.

An interview with Nicholas J. Vogelzang, MD, during the ASCO 2012 Genitourinary Cancers Symposium, about treatment of prostate cancer and unmet needs.

An immunoassay to detect the presence of PAM4 showed promise for the detection and diagnosis of early-stage pancreatic ductal adenocarcinoma.

More research is needed to define molecular subtypes of gastric cancer and identify appropriate targets for clinical use.

For patients with metastatic colorectal cancer that has progressed on multiple lines of standard therapy, regorafenib may be a new treatment option that achieves disease control.

The combination of anastrozole and fulvestrant improved survival when used as first-line therapy in postmenopausal women with metastatic HR-positive breast cancer compared with anastrozole alone.

The developing theme is that bisphosphonates are most effective in postmenopausal patients with HR-positive breast cancer.

The combination of lenalidomide and docetaxel for treatment of CRPC failed to produce results in the large phase III MAINSAIL trial.

Adults with localized Ewing sarcoma have a much lower rate of 5-year survival than do children.

With the discovery of mutation drivers for NSCLC--including EGFR, KRAS, and EMLA 4-ALK--targeted therapies directed to those mutations are beginning to make a difference.

Men with prostate cancer now have an array of treatments, which was not the case a decade ago.

Half of all women with advanced ovarian cancer who develop brain cancer have a single metastasis to the brain.

Not all intermediate-risk prostate cancer patients benefit from the addition of androgen deprivation therapy to radiation therapy.

Patients with limited and extensive SCLC show incremental gains with different treatment strategies but so far novel agents have failed to make a difference in outcomes.